Details for New Drug Application (NDA): 206192
✉ Email this page to a colleague
NDA 206192 describes COTELLIC, which is a drug marketed by Genentech Inc and is included in one NDA. It is available from one supplier. There are seven patents protecting this drug. Additional details are available on the COTELLIC profile page.
The generic ingredient in COTELLIC is cobimetinib fumarate. One supplier is listed for this compound. Additional details are available on the cobimetinib fumarate profile page.
The generic ingredient in COTELLIC is cobimetinib fumarate. One supplier is listed for this compound. Additional details are available on the cobimetinib fumarate profile page.
Summary for 206192
| Tradename: | COTELLIC |
| Applicant: | Genentech Inc |
| Ingredient: | cobimetinib fumarate |
| Patents: | 7 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 206192
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 206192
| Mechanism of Action | Kinase Inhibitors |
Suppliers and Packaging for NDA: 206192
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| COTELLIC | cobimetinib fumarate | TABLET;ORAL | 206192 | NDA | Genentech, Inc. | 50242-717 | 50242-717-01 | 63 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (50242-717-01) |
| COTELLIC | cobimetinib fumarate | TABLET;ORAL | 206192 | NDA | Genentech, Inc. | 50242-717 | 50242-717-86 | 63 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (50242-717-86) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 20MG BASE | ||||
| Approval Date: | Nov 10, 2015 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Jul 28, 2025 | ||||||||
| Regulatory Exclusivity Use: | INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULT OF STUDY GO29665 | ||||||||
| Regulatory Exclusivity Expiration: | Jan 28, 2026 | ||||||||
| Regulatory Exclusivity Use: | PEDIATRIC EXCLUSIVITY | ||||||||
| Regulatory Exclusivity Expiration: | Oct 28, 2025 | ||||||||
| Regulatory Exclusivity Use: | TREATMENT OF ADULT PATIENTS WITH HISTIOCYTIC NEOPLASMS | ||||||||
Complete Access Available with Subscription
